{"id":56610,"date":"2025-07-17T18:14:37","date_gmt":"2025-07-17T16:14:37","guid":{"rendered":"https:\/\/www.fyb.de\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/"},"modified":"2025-07-29T18:14:37","modified_gmt":"2025-07-29T16:14:37","slug":"ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/","title":{"rendered":"ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group"},"content":{"rendered":"<p>Frank\u00adfurt a. Main \u2014 The leading medium-sized inter\u00adna\u00adtio\u00adnal phar\u00admaceu\u00adti\u00adcal company Ethy\u00adph\u00adarm S.A.S., Saint-Clou\u00add\/France has signed a purchase agree\u00adment for the rights to the Euro\u00adpean Arga\u00adtro\u00adban busi\u00adness of Mitsu\u00adbi\u00adshi Tanabe Pharma Corpo\u00adra\u00adtion, Osaka\/Japan and other compa\u00adnies of the Mitsu\u00adbi\u00adshi Tanabe Pharma Group. Arga\u00adtro\u00adban mono\u00adhy\u00addrate is a selec\u00adtive anti\u00adthrom\u00adbin agent used in the treat\u00adment of hepa\u00adrin-indu\u00adced throm\u00adbo\u00adcy\u00adto\u00adpe\u00adnia type II (HIT type II). Due to the company struc\u00adtures, the comple\u00adxity of the rights to the product and the invol\u00advement of other opera\u00adtio\u00adnal inter\u00adme\u00addia\u00adries for the manu\u00adfac\u00adture of the Arga\u00adtro\u00adban active ingre\u00addi\u00adent, the tran\u00adsac\u00adtion was carried out by way of an asset&nbsp;deal.&nbsp;<\/p>\n<p>Ethy\u00adph\u00adarm is a leading mid-sized inter\u00adna\u00adtio\u00adnal phar\u00admaceu\u00adti\u00adcal company with strong Euro\u00adpean roots that manu\u00adfac\u00adtures and supplies essen\u00adtial medi\u00adci\u00adnes with a focus on hospi\u00adtal care, central nervous system (severe pain and addic\u00adtion) and inter\u00adnal medi\u00adcine. The acqui\u00adsi\u00adtion streng\u00adthens Ethy\u00adphar\u00adm\u2019s port\u00adfo\u00adlio of essen\u00adtial medicines.&nbsp;<\/p>\n<p>In addi\u00adtion to Mitsu\u00adbi\u00adshi Tanabe Pharma Corpo\u00adra\u00adtion, the sellers were its subsi\u00addia\u00adries Mitsu\u00adbi\u00adshi Tanabe Pharma Europe Ltd, London\/United King\u00addom and Mitsu\u00adbi\u00adshi Tanabe Pharma GmbH, D\u00fcsseldorf.<\/p>\n<p><strong>Advi\u00adsor Ethy\u00adph\u00adarm: Schad\u00adbach Rechtsanw\u00e4lte<\/strong><\/p>\n<p><strong>Kai Schad\u00adbach, LL.M.<\/strong>  (Photo \u00a9 Schad\u00adbach Rechts\u00adan\u00adw\u00e4lte, lead), Konstan\u00adtin Warno\u00adwizki and S\u00f6ren Brost (all M&amp;A), Dr. Petra Weipert and Annette Kuhlen-Leis (both employ\u00adment law) and Dr. Marco Brand (commer\u00adcial&nbsp;law).<\/p>\n<p><strong>About Schad\u00adbach Attor\u00adneys at&nbsp;Law<\/strong><\/p>\n<p>Schad\u00adbach Rechts\u00adan\u00adw\u00e4lte is a natio\u00adnal and inter\u00adna\u00adtio\u00adnal commer\u00adcial law firm based in Frank\u00adfurt am Main. Our clients are predo\u00admi\u00adnantly medium-sized compa\u00adnies and inter\u00adna\u00adtio\u00adnal groups of compa\u00adnies who value our firm\u2019s exper\u00adtise in corpo\u00adrate law as well as our contrac\u00adtual and tran\u00adsac\u00adtional expe\u00adri\u00adence, e.g. in the M&amp;A and private equity market. In addi\u00adtion to corporate\/M&amp;A, other areas of advice include (inter\u00adna\u00adtio\u00adnal) commer\u00adcial law, direc\u00adtors\u2019 and offi\u00adcers\u2019 liabi\u00adlity and proce\u00addu\u00adral law. \u2014 www.schadbach.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Frank\u00adfurt a. Main \u2014 The leading medium-sized inter\u00adna\u00adtio\u00adnal phar\u00admaceu\u00adti\u00adcal company Ethy\u00adph\u00adarm S.A.S., Saint-Clou\u00ad\u00add\/France has signed a purchase agree\u00adment for the rights to the Euro\u00adpean Arga\u00adtro\u00adban busi\u00adness of Mitsu\u00adbi\u00adshi Tanabe Pharma Corpo\u00adra\u00adtion, Osaka\/Japan and other compa\u00adnies of the Mitsu\u00adbi\u00adshi Tanabe Pharma Group. Arga\u00adtro\u00adban mono\u00adhy\u00addrate is a selec\u00adtive anti\u00adthrom\u00adbin agent used in the treat\u00adment of hepa\u00adrin-indu\u00ad\u00adced thrombocytopenia&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":56608,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1366],"tags":[],"class_list":["post-56610","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group - FYB Financial Yearbook<\/title>\n<meta name=\"description\" content=\"Frankfurt a. Main - The leading medium-sized international pharmaceutical company Ethypharm S.A.S., Saint-Cloud\/France, has concluded a purchase agreement for the rights to the European Argatroban business of Mitsubishi Tanabe Pharma Corporation, Osaka\/Japan and other companies of the Mitsubishi Tanabe Pharma Group. Due to the company structures, the complexity of the rights to the product and the involvement of other operational intermediaries for the manufacture of the Argatroban active ingredient, the transaction was carried out by way of an asset deal.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Frankfurt a. Main - The leading medium-sized international pharmaceutical company Ethypharm S.A.S., Saint-Cloud\/France, has concluded a purchase agreement for the rights to the European Argatroban business of Mitsubishi Tanabe Pharma Corporation, Osaka\/Japan and other companies of the Mitsubishi Tanabe Pharma Group. Due to the company structures, the complexity of the rights to the product and the involvement of other operational intermediaries for the manufacture of the Argatroban active ingredient, the transaction was carried out by way of an asset deal.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-17T16:14:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-29T16:14:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/kai-schadbach-schadbach-rechtsanwaelte.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"397\" \/>\n\t<meta property=\"og:image:height\" content=\"397\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group\",\"datePublished\":\"2025-07-17T16:14:37+00:00\",\"dateModified\":\"2025-07-29T16:14:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/\"},\"wordCount\":308,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/kai-schadbach-schadbach-rechtsanwaelte.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/\",\"url\":\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/\",\"name\":\"ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/kai-schadbach-schadbach-rechtsanwaelte.jpg\",\"datePublished\":\"2025-07-17T16:14:37+00:00\",\"dateModified\":\"2025-07-29T16:14:37+00:00\",\"description\":\"Frankfurt a. Main - The leading medium-sized international pharmaceutical company Ethypharm S.A.S., Saint-Cloud\/France, has concluded a purchase agreement for the rights to the European Argatroban business of Mitsubishi Tanabe Pharma Corporation, Osaka\/Japan and other companies of the Mitsubishi Tanabe Pharma Group. Due to the company structures, the complexity of the rights to the product and the involvement of other operational intermediaries for the manufacture of the Argatroban active ingredient, the transaction was carried out by way of an asset deal.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/kai-schadbach-schadbach-rechtsanwaelte.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/kai-schadbach-schadbach-rechtsanwaelte.jpg\",\"width\":397,\"height\":397},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group - FYB Financial Yearbook","description":"Frankfurt a. Main - The leading medium-sized international pharmaceutical company Ethypharm S.A.S., Saint-Cloud\/France, has concluded a purchase agreement for the rights to the European Argatroban business of Mitsubishi Tanabe Pharma Corporation, Osaka\/Japan and other companies of the Mitsubishi Tanabe Pharma Group. Due to the company structures, the complexity of the rights to the product and the involvement of other operational intermediaries for the manufacture of the Argatroban active ingredient, the transaction was carried out by way of an asset deal.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/","og_locale":"en_US","og_type":"article","og_title":"ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group - FYB Financial Yearbook","og_description":"Frankfurt a. Main - The leading medium-sized international pharmaceutical company Ethypharm S.A.S., Saint-Cloud\/France, has concluded a purchase agreement for the rights to the European Argatroban business of Mitsubishi Tanabe Pharma Corporation, Osaka\/Japan and other companies of the Mitsubishi Tanabe Pharma Group. Due to the company structures, the complexity of the rights to the product and the involvement of other operational intermediaries for the manufacture of the Argatroban active ingredient, the transaction was carried out by way of an asset deal.","og_url":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2025-07-17T16:14:37+00:00","article_modified_time":"2025-07-29T16:14:37+00:00","og_image":[{"width":397,"height":397,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/kai-schadbach-schadbach-rechtsanwaelte.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group","datePublished":"2025-07-17T16:14:37+00:00","dateModified":"2025-07-29T16:14:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/"},"wordCount":308,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/kai-schadbach-schadbach-rechtsanwaelte.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/","url":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/","name":"ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/kai-schadbach-schadbach-rechtsanwaelte.jpg","datePublished":"2025-07-17T16:14:37+00:00","dateModified":"2025-07-29T16:14:37+00:00","description":"Frankfurt a. Main - The leading medium-sized international pharmaceutical company Ethypharm S.A.S., Saint-Cloud\/France, has concluded a purchase agreement for the rights to the European Argatroban business of Mitsubishi Tanabe Pharma Corporation, Osaka\/Japan and other companies of the Mitsubishi Tanabe Pharma Group. Due to the company structures, the complexity of the rights to the product and the involvement of other operational intermediaries for the manufacture of the Argatroban active ingredient, the transaction was carried out by way of an asset deal.","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/kai-schadbach-schadbach-rechtsanwaelte.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/kai-schadbach-schadbach-rechtsanwaelte.jpg","width":397,"height":397},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/56610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=56610"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/56610\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/56608"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=56610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=56610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=56610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}